Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.
Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.
复制标题
JARID1b的过表达与上皮卵巢癌的预后不良和化学疗法抗性有关。
DOI：
10.1007/s13277-014-2859-z
复制
发表时间：
2015-04
期刊：
影响因子：
--
通讯作者：
Han, Shiyu
中科院分区：
文献类型：
--
作者：
Wang, Lishuang;Mao, Yuanfu;Du, Guiqin;He, Chunbo;Han, Shiyu
JARID1B是一种组蛋白去甲基酶，已被报道在多种人类癌症中高表达。本研究探讨JARID1B水平与上皮性卵巢癌及卵巢上皮性癌患者预后的关系。采用定量聚合酶链式反应(qRT-PCR)和免疫印迹法检测了20例正常卵巢、20例良性卵巢肿瘤(BOT)和45例卵巢上皮性癌组织中JARID1B的表达。采用免疫组织化学方法检测120例不同组织学分期的卵巢癌组织中JARID1B的表达。通过单因素和多因素分析确定JARID1B水平与卵巢癌患者预后和化疗耐药的可能相关性。与正常卵巢和BOT相比，卵巢癌组织中JARID1B水平显著升高。在12 0例卵巢癌患者中，JARID1B高表达和低表达患者的5年无进展生存率分别为17%和85%(危险性比 = 为17 85，95%可信区间为6 31~5 0 5 1，P <； 为0.001)。同样，JARID1B高表达和低表达患者的5年总生存率(OS)分别为28%和92%(危险比 = 为21.8，95%CI为5.92-71.81，P <； 为0.001)。卵巢癌患者的化疗耐药与JARID1B水平呈正相关(OR36.81，95%CI4.84~280.11，P <； 0.001)。JARID1B可作为卵巢癌患者预后和化疗耐药的重要生物标志物。
JARID1B, a histone demethylase, has been reported to be highly expressed in various human cancers. In the present study, we investigated the association of JARID1B level with epithelial ovarian cancer (EOC) and prognosis of patients with EOC. We analyzed JARID1B expression in 20 normal ovaries, 20 benign ovarian tumor (BOT) samples, and 45 epithelial ovarian carcinoma specimens by quantitative PCR (qRT-PCR) and western blotting analyses. JARID1B was further examined in 120 EOC specimens from patients with different histological stages via immunohistochemistry. Possible correlations between JARID1B levels and prognosis as well as chemotherapy resistance of EOC patients were determined by univariate and multivariate analyses. JARID1B level was significantly increased in EOC, as compared to normal ovaries and BOT. Among 120 EOC cases examined, the 5-year progression-free survival (PFS) rates were 17 and 85 % in patients with high and low JARID1B expression, respectively (hazard ratio = 17.85, 95 % confidence interval (CI) 6.31–50.51, P < 0.001). Similarly, the 5-year overall survival (OS) rates for patients with high and low JARID1B expression were 28 and 92 % respectively (hazard ratio = 21.8, 95 % CI 5.92–71.81, P < 0.001). Positive correlation between JARID1B level and chemotherapy resistance was observed in patients with EOC (odds ratio (OR) 36.81, 95 % CI 4.84–280.11, P < 0.001). JARID1B could serve as an important biomarker for prognosis and chemotherapy resistance of EOC patients.
登录
查看更多内容
影响因子：
64.5
作者：
Roesch A;Fukunaga-Kalabis M;Schmidt EC;Zabierowski SE;Brafford PA;Vultur A;Basu D;Gimotty P;Vogt T;Herlyn M
通讯作者：
Herlyn M
影响因子：
16
作者：
Yamane, Kenichi;Tateishi, Keisuke;Zhang, Yi
通讯作者：
Zhang, Yi
影响因子：
6.4
作者：
Yin, Mingzhu;Xu, Ye;Zhou, Rouli
通讯作者：
Zhou, Rouli
影响因子：
50.3
作者：
Yamamoto S;Wu Z;Russnes HG;Takagi S;Peluffo G;Vaske C;Zhao X;Moen Vollan HK;Maruyama R;Ekram MB;Sun H;Kim JH;Carver K;Zucca M;Feng J;Almendro V;Bessarabova M;Rueda OM;Nikolsky Y;Caldas C;Liu XS;Polyak K
通讯作者：
Polyak K
影响因子：
6.4
作者：
Barrett, A;Madsen, B;Taylor-Papadimitriou, J
通讯作者：
Taylor-Papadimitriou, J